Log in to search using one of your social media accounts:

 

Lung Transplant Valid in SSc

(MedPage Today) -- Patients with systemic sclerosis shouldn't be denied lung transplants.
Source: MedPage Today Meeting Coverage - Category: Journals (General) Source Type: news

Related Links:

Due to its multisystemic nature, scleroderma (SSc) remains a relative contraindication to lung transplantation in many transplantation centers. However, recent studies suggest that post-transplant outcomes in patients with SSc do not differ significantly from those in patients with interstitial lung diesase (ILD). However, the impact of SSc-associated pulmonary arterial hypertension (PAH) on post transplant outcome remains unknown. Objective: to investigate demographics, survival and prognostic factors in a multicentric cohort of well-characterized patients with SSc lung disease undergoing lung or heart-lung transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
This study intended to clarify the clinical features and prognosis of CTD-PAH and compare between SSc-PAH and other CTD-PAH (non SSc-PAH) in Japanese therapeutic era. .
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc) that warrants early detection. Although resting echocardiography is recommended for screening, exercise echocardiography (EEcho) may detect an abnormal increase in mean pulmonary arterial pressure (PAPm). In addition, multipoint relationship between PAPm and cardiac output (P/Q), a more physiological approach, can be generated during EEcho. Our objective was to analyze the P/Q relationship in SSc patients compared with matched controls.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Due to its multisystemic nature, scleroderma is considered a relative contraindication to lung transplantation at many centers. However, recent studies suggest similar post-transplant outcomes in patients with scleroderma compared to those with other causes of interstitial lung disease (ILD). Furthermore, it remains unknown whether scleroderma-associated pulmonary arterial hypertension (PAH) influences post-transplant outcomes. Our objective in this study was to assess the indications, survival, and prognostic factors of lung or heart –lung transplantation for scleroderma lung disease.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Due to its multisystemic nature, scleroderma is considered a relative contra-indication to lung transplantation in many centers. However, recent studies suggest similar post-transplant outcomes in patients with scleroderma compared to those with other causes of interstitial lung disease (ILD). Furthermore, whether scleroderma-associated pulmonary arterial hypertension (PAH) influences post-transplant outcomes remains unknown. Our objective here was to assess the indications, survival, and prognostic factors of lung or heart-lung transplantation for scleroderma lung disease.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Due to its multisystemic nature, scleroderma is considered a relative contraindication to lung transplantation at many centers. However, recent studies suggest similar post-transplant outcomes in patients with scleroderma compared to those with other causes of interstitial lung disease (ILD). Furthermore, it remains unknown whether scleroderma-associated pulmonary arterial hypertension (PAH) influences post-transplant outcomes. Our objective in this study was to assess the indications, survival, and prognostic factors of lung or heart –lung transplantation for scleroderma lung disease.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer?, Published online: 08 March 2018; doi:10.1038/nrrheum.2018.34Autologous haematopoietic stem cell transplantation (HSCT) has proved efficacious in treating patients with systemic sclerosis, but different regimens have different associated toxicities and different effects on lung function. Through comparison of different clinical trials, we can learn how to improve the safety of HSCT.
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Source Type: research
Authors: Boucly A, Girerd B, Bourlier D, Nemlaghi S, Caliez J, Savale L, Jaïs X, Dorfmüller P, Simonneau G, Sitbon O, Humbert M, Montani D Abstract Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension (PH) characterized by preferential remodelling of pulmonary venules and angioproliferation. PVOD term includes idiopathic, heritable (biallelic mutations of EIF2AK4 gene), drugs and toxins induced (alkylating agents, organic solvents) and connectivite-associated forms (especially systemic-sclerosis associated form). PVOD and pulmonary arterial hypertension (PAH) share a simil...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
In this study, 36 people with severe scleroderma received stem-cell transplantation and were compared with 39 otherwise similar people who received a year of standard immune-suppressing medication. After 4.5 years, those assigned to receive stem-cell transplantation had improved overall survival compared with standard treatment (79% vs. 50%) less need for immune-suppressing medication (9% vs. 44%) fewer deaths related to worsening scleroderma (11% vs. 28%) more deaths related to treatment — (3% vs. 0%). These findings suggest that stem-cell transplantation may be much better than standard treatment for people with ...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Autoimmune diseases Health Skin and Hair Care Source Type: blogs
Conclusions Despite being at high risk for extrapulmonary complications, patients undergoing bilateral lung transplantation for scleroderma have similar 1-year and 5-year survival as those with restrictive lung disease. Transplantation is a reasonable treatment option for a carefully selected population of candidates.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
More News: General Medicine | Lung Transplant | Scleroderma | Transplant Surgery | Transplants